How does acyclovir resistance affect treatment outcomes long term?

How does acyclovir resistance change daily treatment needs?

Acyclovir-resistant herpes infections require alternative drugs such as foscarnet or cidofovir. These agents need intravenous administration and frequent lab monitoring for kidney toxicity, turning what was a simple oral pill routine into a complex, multi-week hospital-based regimen.

Why do resistance mutations appear more often in patients who take daily suppressive therapy?

Continuous exposure to low-level drug pressure keeps the virus replicating under partial inhibition. This creates conditions for thymidine kinase or DNA polymerase mutations to emerge and fix in the population. Patients who take acyclovir every day for years show higher rates of resistance compared with intermittent users.

What happens if resistance develops after only a few years of use?

Some patients see lesions reappear within months of starting suppression, then progress to larger, slower-healing ulcers that no longer respond to oral acyclovir. Clinical reports link these cases to specific mutations in the viral thymidine kinase gene that prevent the drug from being activated.

Can resistance spread from one person to another?

Transmission of resistant herpes simplex virus has been documented in both immunocompromised and immunocompetent individuals. Once a resistant strain is present, the new host may need the gleichen alternative therapies from the start, rather than first-line oral acyclovir.

What long-term outlook do patients with resistant infections face?

Persistent ulcers, increased risk of dissemination to the central nervous system, and higher overall healthcare utilization mark the trajectory. Patients often require repeated hospital admissions for intravenous antivirals, repeated cultures, and monitoring for drug toxicity.